Pediatric Drug Development in the UAE: Legal Guide
The UAE has built a robust healthcare system in which pediatric medicine is a critical part. This guide explains the legal framework for developing medicines for children.
The UAE has built a robust healthcare system in which pediatric medicine is a critical part. This guide explains the legal framework for developing medicines for children.
Reviewed by Mohamed Noureldin, Founder, Managing Partner & Senior Legal Consultant
Pediatric Drug Development in the UAE: Legal and Regulatory Framework
Related Services: Explore our healthcare legal services and criminal case representation services for practical legal support in this area.
Introduction
The United Arab Emirates (UAE) has built a robust and sophisticated healthcare system, and pediatric medicine is a critical part of it. Pediatric drug development in the UAE, together with the regulation and use of medicines for children, is a strategic priority. It reflects the nation's commitment to protecting the health of its youngest and most vulnerable population.
Children, from neonates to adolescents, have physiological, metabolic and developmental characteristics that demand a distinct, highly regulated approach to drug development. This approach is fundamentally different from the established model for adults. It is not merely a matter of adjusting dosage. It involves addressing variations in drug absorption, distribution, metabolism and excretion (ADME) that change as a child grows.
This article analyses the legal and regulatory framework governing pediatric drug development in the UAE. It examines the key requirements, procedural obligations and strategic implications for organisations operating in this sector. Regulatory compliance here is demanding and requires a detailed understanding of the framework put in place to ensure the safety, efficacy and quality of children's medicines in the UAE.
The analysis is intended as a practical guide for pharmaceutical companies, healthcare providers and legal practitioners working in this complex, high-stakes field. It calls for a proactive, well-planned approach to managing legal and operational risk.
Legal Framework and Regulatory Overview
The legal framework governing pediatric drug development in the UAE is a multi-layered, hierarchical system of federal laws, ministerial decrees and regulatory guidelines. The foundational legislation is Federal Law No. (8) of 2019 on Medical Products, Pharmacy Profession and Pharmaceutical Establishments. It establishes the overall structure for regulating all medical products in the state, including its free zones.
This primary law is put into effect through regulations and circulars issued by the Ministry of Health and Prevention (MOHAP) and the newly formed Emirates Drug Establishment (EDE). The EDE is the federal entity tasked with overseeing the entire lifecycle of medical products, from initial research to post-marketing surveillance. Its establishment signals a move towards a more centralised and streamlined regulatory authority, aiming to improve efficiency and align with established global standards.
The pediatric drug landscape in the UAE is further defined by specific guidelines for conducting clinical trials, most notably those issued by the Department of Health - Abu Dhabi (DOH). These guidelines set out a detailed procedural framework for the ethical and scientific conduct of clinical research. They include specific provisions for studies involving children, who are legally and ethically classified as a vulnerable population. This classification triggers a higher level of scrutiny and additional protective measures.
The framework is deliberately designed to be both rigorous and adaptable. It allows the integration of global standards from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), while addressing the UAE's own public health requirements. Regulatory review and marketing authorisation act as a critical control point, ensuring that only medical products with a proven positive risk-benefit profile are made available to children.
The strength of this framework is essential to managing the inherent risks of drug development and protecting children who take part in clinical trials. The imbalance of power between large, well-funded pharmaceutical sponsors and individual patients and their families is a key consideration. The framework seeks to reduce it through stringent informed consent processes, mandatory independent ethical oversight and transparent safety reporting.
Key Requirements and Procedures for Pediatric Drug Development in the UAE
The regulatory pathway for pediatric drug development in the UAE requires strict adherence to a series of demanding requirements and procedures. These processes are thorough and exacting, reflecting the high level of scrutiny applied to products intended for children. The journey from laboratory concept to clinical use is governed by a sequence of mandatory checkpoints.
Clinical Trial Authorisation and Conduct
Authorisation of a clinical trial for a pediatric drug is a rigorous, multi-stage process that begins long before the first patient is enrolled. The sponsor must submit a full application dossier to the relevant regulatory authorities, primarily the EDE and MOHAP.
The dossier must contain, at a minimum:
- the detailed clinical trial protocol;
- the comprehensive Investigator's Brochure (IB), compiling all non-clinical and clinical data; and
- verifiable evidence of manufacturing in compliance with Good Manufacturing Practice (GMP).
The regulators conduct a critical review of the application. They scrutinise the scientific justification, the statistical validity of the study design, the proposed patient population and the adequacy of the measures in place to protect trial subjects.
The DOH Guidelines for Conducting Clinical Trials provide a detailed framework for this process. They require that the expected therapeutic benefits for the individual child and for public health must justify the foreseeable risks. Approval is strictly contingent on a positive opinion from a recognised Research Ethics Committee (REC). The authorisation process, from initial submission to final approval, is designed to control risk and confirm that the proposed research is scientifically and ethically sound before any child is exposed to an investigational product.
Ethical Oversight and Informed Consent
Ethical considerations are the foundation of pediatric clinical research and a non-negotiable prerequisite for any study. The DOH guidelines place strong emphasis on the protection of vulnerable subjects.
A core requirement is obtaining informed consent. This must be secured in writing from both parents or the legal guardian(s) of any child participating in a clinical trial. It is not a mere formality. The consent process must be a full dialogue, conducted in understandable language, that explains the purposes, procedures, risks, inconveniences and potential benefits of the trial. It must also explicitly state the subject's right to withdraw at any time without penalty.
The guidelines also require that the assent of the child, meaning their affirmative agreement to participate, must be obtained if they are old enough to understand the basic nature of the trial. This dual-consent mechanism is a critical safeguard. It addresses the unequal relationship between researchers and pediatric subjects and ensures the child has a voice in the decision. The investigator must respect a minor's declared wish to refuse participation or to withdraw at any time.
The REC provides the primary layer of independent ethical oversight. It reviews and approves trial protocols, consent forms and all patient-facing materials, so that the rights, safety and well-being of children remain the paramount consideration throughout the trial.
Pharmacovigilance and Safety Reporting
Regulatory oversight does not end once a drug is approved. It extends throughout the product's lifecycle through a stringent pharmacovigilance system, and sponsors and investigators are legally required to carefully monitor and report adverse events.
A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalisation, or results in persistent or significant disability. Any SAE that occurs during a clinical trial must be reported immediately to the sponsor. The sponsor, in turn, must report it to the regulatory authorities within strict, legally defined timelines (e.g., within seven calendar days for fatal or life-threatening suspected unexpected serious adverse reactions).
This reporting system is a critical part of the risk management framework. It allows regulators to continuously monitor the safety profile of children's medicines in the UAE and take decisive protective action if necessary. Such action can include suspending a trial, demanding protocol amendments or issuing urgent safety communications to healthcare professionals. The objective is a proactive, data-driven system for identifying, evaluating and addressing potential safety hazards, ensuring the long-term protection of children.
| Procedural Stage | Key Requirement | Primary Oversight Body |
|---|---|---|
| Pre-Clinical Phase | Pharmacological and toxicological studies according to Good Laboratory Practice (GLP). | EDE / MOHAP |
| Clinical Trial Application | Submission of a complete dossier including protocol, IB, and GMP evidence. | EDE / MOHAP |
| Ethical Review | Independent review and approval of the trial protocol and informed consent documents. | Research Ethics Committee (REC) |
| Informed Consent | Obtain written consent from parent(s)/guardian(s) and assent from the child. | Principal Investigator / REC |
| Safety Reporting | Mandatory and expedited reporting of all Serious Adverse Events (SAEs). | EDE / MOHAP |
| Manufacturing | Production of investigational products must adhere to Good Manufacturing Practice (GMP). | EDE / MOHAP |
| Post-Marketing | Ongoing pharmacovigilance and submission of periodic safety update reports (PSURs). | EDE / MOHAP |
Strategic Implications
The highly structured and demanding legal framework for pediatric drug development in the UAE has significant strategic implications for all stakeholders.
Pharmaceutical companies must put in place a multi-disciplinary, well-resourced regulatory strategy to navigate the complex approval process successfully. This requires a deep, technical understanding of local laws and guidelines. It also requires the ability to explain the clinical value and risk-mitigation strategy of their products clearly to sceptical regulators. There is zero tolerance for procedural shortcuts or incomplete data, and the financial and operational investment is substantial, requiring long-term commitment.
Healthcare providers operate under a significant duty of care. They must stay current with the approved indications, contraindications and emerging safety profiles of the drugs they prescribe to children.
For legal practitioners, this specialised field demands combined expertise in healthcare law and regulatory affairs. Lawyers provide critical counsel to clients on compliance, liability, market access strategies and intellectual property protection.
The gap in resources and information between large, multinational pharmaceutical sponsors and local healthcare providers and patients calls for a collaborative and transparent approach, so that the ultimate goal, the health of the child, is achieved. Success in the UAE's pediatric market depends on a long-term commitment to quality, safety and consistent regulatory compliance. For more information on our legal services, please visit the Nour Attorneys website.
Conclusion
The UAE has developed a comprehensive and rigorous legal and regulatory framework for pediatric drug development. It is clearly designed to ensure the highest standards of safety, efficacy and quality for medicines intended for children, while also supporting responsible innovation.
The rigour of the regulatory review process, combined with a firm focus on ethical principles such as dual consent and independent oversight, creates a strong system for protecting children. Navigating this demanding landscape requires a strategic, proactive and carefully planned approach from all stakeholders, from the research bench to the patient's bedside. As the UAE strengthens its position as a leading global healthcare destination, the growth of a sophisticated and ethically grounded pediatric drug market will be a key measure of its success.
At Nour Attorneys, we have the specialised expertise to guide your organisation through every stage of this process. Our experienced legal team provides the counsel you need to achieve your objectives in the UAE healthcare sector. Contact us today to learn how we can support you. We also advise on corporate law, real estate law and intellectual property.
Additional Resources
Explore more of our insights on related topics: